Clinical Insights in Genitourinary Cancer
Bladder cancer in 2024: health equity, combo regimens and more
In 2024, the treatment landscape for bladder cancer evolved, with new breakthroughs in combination therapies, new challenges and an emphasis on addressing disparities in care.
This review explores five key updates, offering an overview of where bladder cancer research, treatment and health equity efforts stand as a new year approaches.
Read more in Genitourinary Cancer
1. Gilead Sciences announced its intention to voluntarily withdraw the accelerated approval for sacituzumab govitecan-hziv (Trodelvy, Gilead Sciences) for treatment of certain patients with advanced bladder cancer. Read more.
2. The combination of durvalumab (Imfinzi, AstraZeneca) and chemotherapy improved outcomes compared with neoadjuvant chemotherapy alone for patients with muscle-invasive bladder cancer, according to the agent’s manufacturer. Read more.
3. Immunotherapy utilization for treatment of advanced kidney or bladder cancers varied by patients’ race or socioeconomic status, according to study results. Read more.
4. Extended lymphadenectomy offered no survival benefit for patients with localized muscle-invasive bladder cancer compared with bilateral standard lymphadenectomy for patients undergoing radical cystectomy, according to study findings. Read more.
5. Use of durvalumab before and after radical cystectomy improved outcomes for patients with muscle-invasive bladder cancer, according to results of the randomized phase 3 NIAGARA trial. Read more.
